Answers are grounded in this paper and cite their sources.
Alzheimer's disease (AD) is a common chronic and destructive disease. The early diagnosis of AD is difficult, thus the need for clinically applicable biomarkers development is growing rapidly. There are many methods to biomarker discovery and identification. In this review, we aim to summarize Mass spectrometry (MS)-based proteomics studies on AD and discuss thoroughly the methods to identify candidate biomarkers in cerebrospinal fluid (CSF) and blood. This review will also discuss the potential research areas on biomarkers.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: